- Arcinova has reintroduced its brand under Quotient Sciences, launching a new website and updated communication channels.
- The move aims to better define service structures while maintaining shared ownership and operational continuity.
Arcinova, acquired by Quotient Sciences in 2021, has launched a refreshed brand presence, including a dedicated website and new communications structure. The rebranding aims to clarify the distinct but complementary roles Arcinova and Quotient Sciences play within the broader drug development pathway.
Operating from Alnwick and Reading, UK, Arcinova provides integrated drug substance and drug product services, with specialities in bioanalysis, isotope labelling, aseptic manufacturing, microbiology, and inhaled drug delivery.
Quotient Sciences continues to operate sites in Nottingham, Edinburgh, Philadelphia, and Miami, offering Translational Pharmaceutics® programmes, clinical pharmacology studies, and formulation-to-manufacturing services. Together, the two brands form a cohesive drug development platform.
The rebrand brings new email domains and a dedicated enquiry address, but there are no changes to purchasing, invoicing, or IT systems. Arcinova remains under the Quotient Sciences ownership structure.
